Danaher Corporation

5 days ago · zacks.com

Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

11 days ago · zacks.com

Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?

11 days ago · seekingalpha.com

Danaher Corporation is rated hold, as the stock trades at a small premium and offers an 8.85% expected return, below my threshold. Q3 earnings showed solid performance: revenue up 8.3% YoY to $6.55B, adjusted EPS of $2.11, and strong segment growth, especially in Diagnostics. Key headwinds include respiratory revenue volatility and pricing pressure from China's volume-based procurement, despite some recent positive trends.

12 days ago · fool.com

It beat analyst estimates for both revenue and profitability. Its full-year earnings guidance also topped the pundit consensus.

12 days ago · seekingalpha.com

Danaher Corporation ( DHR ) Q3 2026 Earnings Call October 21, 2026 8:00 AM EDT Company Participants Rachel Vatnsdal Olson - Vice President of Investor Relations Julie Montgomery - President, CEO & Director Matthew Gugino - Executive VP & CFO Conference Call Participants Doug Schenkel Vijay Kumar - Evercore ISI Institutional Equities, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Operon Research, LLC Scott Davis - Melius Research LLC Casey Woodring - JPMorgan Chase & Co, Research Division Elizabeth Koslosky - Goldman Sachs Group, Inc., Research Division Presentation Operator My name is Chelsea, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2026 Earnings Results Conference Call.

12 days ago · fool.com

Danaher raised full-year earnings per share guidance to $8.57 to $8.62. Biotechnology orders grew mid-teens during the third quarter.

12 days ago · seekingalpha.com

Danaher Corporation delivered mixed Q3 results, with revenue up 8.3% y/y but growth driven mainly by acquisitions and tariff refunds. Adjusted operating margin reached 29%, exceeding guidance, yet organic growth and profitability improvements remain modest and partly non-recurring. Management's Q4 guidance implies lower-than-expected EPS, and the new CEO signals a need for stronger growth and operational execution.

12 days ago · zacks.com

Danaher's third-quarter earnings beat estimates by 9.9%, driven by stronger Biotechnology profitability, while it raised its 2026 adjusted earnings outlook.

12 days ago · benzinga.com

Danaher Corp. (NYSE:DHR) on Wednesday reported third-quarter adjusted earnings of $2.11 per share, beating the analyst consensus estimate of $1.92.

12 days ago · marketbeat.com

Danaher NYSE: DHR reported third-quarter 2026 results that exceeded its expectations, citing improved market conditions, commercial execution and operational performance across its Biotechnology, Life Sciences and Diagnostics businesses.